Why a compounded vial and a brand pen are not prices for the same product

This site is run by the editorial team of a company that sells compounded semaglutide and tirzepatide. That is the reason to be exact here rather than a reason to be vague. A compounded vial and an approved pen can both be priced, and both are priced on this site, but they are not two prices for one thing.

What approval covers

Wegovy, Ozempic, Zepbound and Mounjaro are approved drugs. The FDA reviewed their manufacturing, their stability, their clinical trials and their labelling, and it inspects the plants that make them. The label tells a prescriber the dose schedule, the contraindications and the adverse-event rates from named trials. The pen delivers a fixed dose. The manufacturer is accountable for the product.

A compounded preparation is made by a pharmacy under state licence (503A) or by an outsourcing facility registered with the FDA (503B) from bulk active ingredient. The FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness or quality before they are marketed. There is no label in the regulatory sense, no trial of the preparation, and the concentration on the vial is the pharmacy's statement. The FDA has documented dosing errors with compounded semaglutide arising from confusion between units, millilitres and milligrams on vials and syringes.

What the shortage dates changed

Federal law lets compounders make what is essentially a copy of an approved drug only while that drug is on the FDA shortage list. The FDA declared the tirzepatide shortage resolved on December 19, 2024, with enforcement discretion for 503A pharmacies until February 18, 2025 and 503B facilities until March 19, 2025, and the semaglutide shortage resolved on February 21, 2025, with discretion until April 22 and May 22, 2025. Compounding since then rests on other grounds (a documented clinical difference for a specific patient, for instance), and on April 30, 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substance; comments closed June 29, 2026. Whether a given provider's compounded product is lawfully made is a question this site does not answer and its price table does not imply.

Why the prices are built differently

A brand product has a list price, a set of manufacturer programs discounted from it, and an insurance path. As of September 4, 2026: Zepbound lists at $1,088 a month and sells for $299 to $449 self-pay; Wegovy lists at $1,349.02 and sells for $199 then $349. The self-pay price is the same at every LillyDirect or NovoCare checkout in the country and includes the drug and delivery, nothing else.

A compounded product has no list price. The pharmacy or the telehealth provider sets a price for its own preparation, and the price bundles different things at different providers: medication only; medication plus a mandatory membership; a first month bundled with an intake visit; a prepaid three- or twelve-month term. Two providers quoting $299 may be quoting a 10 mg vial and a 30 mg vial, with or without a $79 fee on top. That is why the compounded table is built on an all-in, 28-day, dated unit with an observation method on every row, and why it keeps brand reference prices in a separate series.

What is inside each price

How to compare when you must

People do compare them, because the numbers are next to each other in their lives. If you are going to:

• Compare all-in to all-in over the same period. A brand fill is 28 days with nothing added; a compounded offer needs its fees, shipping and any minimum term added before it is a 28-day figure.
• Compare at the same dose step. Month one and month four differ on both sides.
• Treat a compounded per-mg figure as depending on a concentration the FDA has not checked.
• Do not read a lower price as equivalence. The price per mg page sets out where per-mg arithmetic holds and where it does not.
• Put the question to your prescriber and pharmacist. This site prices; it does not advise.

FormBlends' own compounded offer sits in the table under the same rules as its competitors', with its undisclosed recurring price recorded as blank. Nothing on this site links that table to a checkout.